Asked by: Peter Kyle (Labour - Hove and Portslade)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent estimate he has made of (a) the number of referrals received by Child and Adolescent Mental Health Services and (b) childhood obesity rates in each London borough.
Answered by Nadine Dorries
The information requested is attached.
Asked by: Peter Kyle (Labour - Hove and Portslade)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to assess the effectiveness of covid-19 vaccines for those with compromised immune systems.
Answered by Nadhim Zahawi
Public Health England is working with a range of partners to monitor the effectiveness of COVID-19 vaccinations in clinical risk groups, including those with immunosuppression.
Public Health England recently published data on COVID-19 vaccine effectiveness for clinical risk groups. It showed that for those who are immunosuppressed, vaccine effectiveness after a second COVID-19 vaccine dose is 74%, with similar protection to those who are not in a risk group. This rises from 4% after a first dose of COVID-19 vaccine.
Asked by: Peter Kyle (Labour - Hove and Portslade)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with EU counterparts to help ensure that UK citizens who received an Indian-made AstraZeneca vaccine will be able to participate in travel arrangements with the EU.
Answered by Nadhim Zahawi
The Government continues to engage with the European Union on certification to ensure that travel between the United Kingdom and the EU is supported by a common approach.
The Serum Institute of India (SII) manufactures both Vaxzevria and Covishield, branded vaccines which are the same as the University of Oxford/AstraZeneca vaccine. All SII-made doses approved by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) and administered in the UK were branded as the ’COVID-19 vaccine AstraZeneca’ which is now known commercially as ‘Vaxzevria’. The MHRA has not approved doses branded as ‘Covishield’ and none have been administered in the UK. All AstraZeneca vaccines given in the UK are the same product and appear on the NHS COVID Pass as Vaxzevria. The European Medicines Agency has authorised the Vaxzevria vaccine and it is therefore recognised by the EU.
Asked by: Peter Kyle (Labour - Hove and Portslade)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the cumulative number is of covid-19 vaccine doses found not suitable for use, by (a) vaccine type and (b) NHS Region of residence, since January 2021.
Answered by Nadhim Zahawi
The data is not held centrally in the format requested.
Asked by: Peter Kyle (Labour - Hove and Portslade)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how the notional PrEP allocation of £577,957 in the Public Health Grant 2021-2022 for Brighton and Hove Council was calculated.
Answered by Jo Churchill
Notional pre-exposure prophylaxis (PrEP) funding allocations were calculated using a formula that considers the costs associated with continuing to deliver PrEP to residents who who received it through the PrEP Impact Trial and once the trial ended in October 2020, as well as to residents who would be starting PrEP for the first time during 2021-22. This approach was informed by feedback on the 2020/21 PrEP allocations from commissioner representatives and sexual health providers.
Asked by: Peter Kyle (Labour - Hove and Portslade)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the prevalence of long covid symptoms in children.
Answered by Nadine Dorries
No specific assessment has been made.
Asked by: Peter Kyle (Labour - Hove and Portslade)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, in each of the last five years, how many (a) referrals were made by youth offending teams to children and young people's mental health services (CYPMHS), and (b) children referred by youth offending teams to CYPMHS received support.
Answered by Nadine Dorries
The information is not held in the format requested Data showing the referrals made by youth offending teams to children and young people’s mental health services is only available from 2019/20. Prior to 2019/20, such referrals were included in the total referrals made by the wider justice system.
Available data shows that in 2019/20, there were 845 referrals made by youth offending teams to children and young people's mental health services and 483 children and young people were in contact with mental health services after being referred by youth offending teams. Data showing the number of children and young people receiving support is not available.
Asked by: Peter Kyle (Labour - Hove and Portslade)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress has been made on supplying high risk supported living care settings with rapid tests as proposed in the November Covid-19 Winter Plan presented by the Prime Minister.
Answered by Helen Whately - Shadow Secretary of State for Work and Pensions
Following the single round of national testing in the most high-risk extra care and supported living settings, we launched regular polymerase chain reaction retesting on 9 December with weekly testing for staff and monthly for residents. We currently we do not offer any rapid lateral flow device testing for high-risk supported living settings. However, we are currently reviewing our position and will provide more information in due course.